Randomized Trialhigh evidence
Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis.
The New England journal of medicine·November 5, 2026·PMID 42981569
Why it mattersSevere hypertriglyceridemia carries a substantial risk of acute pancreatitis, and current options often fail to achieve adequate triglyceride lowering. Plozasiran’s marked reduction in triglycerides and pancreatitis events offers a potential new therapeutic approach for high-risk patients.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled